OBJECTIVES: This study examined changes in healthcare use among perinatally HIV-infected children and developed new estimates of expected lifetime treatment costs. METHODS: The study analyzed longitudinal medical record data from the Pediatric Spectrum of Disease study on perinatally HIV-infected children enrolled in 6 US sites during 1995 and 2001 for enrollee characteristics including healthcare utilization. For the year 2001, costs were assigned to hospitalization, HIV-related drug usage, and laboratory testing. To estimate lifetime treatment costs based on those categories, median survival times of 9, 15, and 25 years were assumed and average annual healthcare utilization costs were applied to each year of survival. RESULTS: From 1995 to 2001, hospitalization rates fell from 0.67 per child-year to 0.23 per child-year (P < 0.05). In 2001, the average cost of healthcare utilization per child was $12,663, including $2164 for hospitalization, $9505 for HIV-related drugs, and $994 for laboratory tests. The discounted lifetime treatment cost, based on those 3 cost categories, was $113,476 for 9 years of survival, $151,849 for 15 years, and $228,155 for 25 years. CONCLUSIONS: Hospitalizations among perinatally HIV-infected children decreased significantly from 1995 to 2001. Compared with previously published estimates, lifetime treatment costs for children perinatally infected with HIV have remained relatively stable. However, as years of survival increase for this population, lifetime costs also are likely to increase.
OBJECTIVES: This study examined changes in healthcare use among perinatally HIV-infectedchildren and developed new estimates of expected lifetime treatment costs. METHODS: The study analyzed longitudinal medical record data from the Pediatric Spectrum of Disease study on perinatally HIV-infectedchildren enrolled in 6 US sites during 1995 and 2001 for enrollee characteristics including healthcare utilization. For the year 2001, costs were assigned to hospitalization, HIV-related drug usage, and laboratory testing. To estimate lifetime treatment costs based on those categories, median survival times of 9, 15, and 25 years were assumed and average annual healthcare utilization costs were applied to each year of survival. RESULTS: From 1995 to 2001, hospitalization rates fell from 0.67 per child-year to 0.23 per child-year (P < 0.05). In 2001, the average cost of healthcare utilization per child was $12,663, including $2164 for hospitalization, $9505 for HIV-related drugs, and $994 for laboratory tests. The discounted lifetime treatment cost, based on those 3 cost categories, was $113,476 for 9 years of survival, $151,849 for 15 years, and $228,155 for 25 years. CONCLUSIONS: Hospitalizations among perinatally HIV-infectedchildren decreased significantly from 1995 to 2001. Compared with previously published estimates, lifetime treatment costs for children perinatally infected with HIV have remained relatively stable. However, as years of survival increase for this population, lifetime costs also are likely to increase.
Authors: Anne M Neilan; Brad Karalius; Kunjal Patel; Russell B Van Dyke; Mark J Abzug; Allison L Agwu; Paige L Williams; Murli Purswani; Deborah Kacanek; James M Oleske; Sandra K Burchett; Andrew Wiznia; Miriam Chernoff; George R Seage; Andrea L Ciaranello Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Kristen M Little; Allan W Taylor; Craig B Borkowf; Maria C B Mendoza; Margaret A Lampe; Paul J Weidle; Steven R Nesheim Journal: Pediatr Infect Dis J Date: 2017-01 Impact factor: 2.129
Authors: Leslie S Wilson; Lori Hensic; Carly J Paoli; Rituparna Basu; Maria Christenson; Judith T Moskowitz; Diane Wara Journal: AIDS Care Date: 2011-07-25
Authors: Sophie Desmonde; Patrick A Coffie; Edmond A Aka; Clarisse Amani-Bosse; Eugène Messou; François Dabis; Andrea Ciaranello; Valériane Leroy Journal: J Acquir Immune Defic Syndr Date: 2013-01-01 Impact factor: 3.731
Authors: Benn K D Sartorius; Kathleen Kahn; Penelope Vounatsou; Mark A Collinson; Stephen M Tollman Journal: BMC Public Health Date: 2010-10-26 Impact factor: 3.295
Authors: Olufunke Fasawe; Carlos Avila; Nathan Shaffer; Erik Schouten; Frank Chimbwandira; David Hoos; Olive Nakakeeto; Paul De Lay Journal: PLoS One Date: 2013-03-12 Impact factor: 3.240